{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T22:58:57Z","timestamp":1770505137596,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1124\/jpet.105.097568","type":"journal-article","created":{"date-parts":[[2006,5,16]],"date-time":"2006-05-16T00:53:36Z","timestamp":1147740816000},"page":"495-502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Discovery and Characterization of Triaminotriazine Aniline Amides as Highly Selective p38 Kinase Inhibitors"],"prefix":"10.1016","volume":"318","author":[{"given":"Tsung H.","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Diller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhuri","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulzar","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Earl F.","family":"Kimble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Quadros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria L.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.105.097568_bib1","doi-asserted-by":"crossref","unstructured":"Adams JL, Badger AM, Kumar S, and Lee JC (2001) p38 MAP kinase: molecular target for the inhibition of proinflammatory cytokines. Prog Med Chem 38: 1-60.","DOI":"10.1016\/S0079-6468(08)70091-2"},{"key":"10.1124\/jpet.105.097568_bib2","doi-asserted-by":"crossref","unstructured":"Allen M, Svensson L, Roach M, Hambor J, McNeish J, and Gabel CA (2000) Deficiency of the stress kinase p38\u03b1 results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells. J Exp Med 191: 859-869.","DOI":"10.1084\/jem.191.5.859"},{"key":"10.1124\/jpet.105.097568_bib3","doi-asserted-by":"crossref","unstructured":"Cirillo PF, Pargellis C, and Regan J (2002) The non-diaryl heterocycle classes of p38 MAP kinase inhibitors. Curr Top Med Chem 2: 1021-1035.","DOI":"10.2174\/1568026023393390"},{"key":"10.1124\/jpet.105.097568_bib4","doi-asserted-by":"crossref","unstructured":"Cvetkovic RS and Keating G (2002) Anakinra. BioDrugs 16: 303-311.","DOI":"10.2165\/00063030-200216040-00005"},{"key":"10.1124\/jpet.105.097568_bib5","doi-asserted-by":"crossref","unstructured":"Diller DJ and Hobbs DW (2004) Deriving knowledge through data mining high-throughput screening data. J Med Chem 47: 6373-6383.","DOI":"10.1021\/jm049902r"},{"key":"10.1124\/jpet.105.097568_bib6","doi-asserted-by":"crossref","unstructured":"Diller DJ, Lin TH, and Metzger A (2005) The discovery of novel chemotypes of p38 inhibitors. Curr Top Med Chem 5: 953-965.","DOI":"10.2174\/1568026054985948"},{"key":"10.1124\/jpet.105.097568_bib7","doi-asserted-by":"crossref","unstructured":"Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23: 329-336.","DOI":"10.1038\/nbt1068"},{"key":"10.1124\/jpet.105.097568_bib8","doi-asserted-by":"crossref","unstructured":"Frantz B, Klatt T, Pang M, Parsons J, Rolando A, Williams H, Tocci MJ, O\u2019Keefe SJ, and O\u2019Neill EA (1998) The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry 37: 13846-13853.","DOI":"10.1021\/bi980832y"},{"key":"10.1124\/jpet.105.097568_bib9","unstructured":"Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, and Chartash EK (2003) Adalimumab, a fully human antitumor necrosis factor-a monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid arthritis). J Rheumatol 30: 2563-2571."},{"key":"10.1124\/jpet.105.097568_bib10","doi-asserted-by":"crossref","unstructured":"Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S, Gutbrod H, Salassidis K, Stein-gerlach M, Missio A, Cotten M, et al. (2003) An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci USA 100: 15434-15439.","DOI":"10.1073\/pnas.2535024100"},{"key":"10.1124\/jpet.105.097568_bib11","doi-asserted-by":"crossref","unstructured":"Goedert M, Cuenda A, Craxton M, Jakes R, and Cohen P (1997) Activation of the novel stress-activated protein kinase SAPK4 by cytokines and cellular stresses is mediated by SKK3 (MKK6): comparison of its substrate specificity with that of other SAP kinases. EMBO (Eur Mol Biol Organ) J 16: 3563-3571.","DOI":"10.1093\/emboj\/16.12.3563"},{"key":"10.1124\/jpet.105.097568_bib12","doi-asserted-by":"crossref","unstructured":"Hatakeyama M, Mori H, Doi T, and Taniguchi T (1989) A restricted cytoplasmic region of IL-2 receptor beta chain is essential for growth signal transduction but not for ligand binding and internalization. Cell 59: 837-845.","DOI":"10.1016\/0092-8674(89)90607-7"},{"key":"10.1124\/jpet.105.097568_bib13","doi-asserted-by":"crossref","unstructured":"Henry JR, Cavender DE, and Wadsworth SA (1999) p38 mitogen-activated protein kinase as a target for drug discovery. Drugs Future 24: 1345-1354.","DOI":"10.1358\/dof.1999.024.12.858635"},{"key":"10.1124\/jpet.105.097568_bib14","doi-asserted-by":"crossref","unstructured":"Jackson PF and Bullington JL (2002) Pyridinylimidazole based p38 MAP kinase inhibitors. Curr Top Med Chem 2: 1011-1020.","DOI":"10.2174\/1568026023393372"},{"key":"10.1124\/jpet.105.097568_bib15","doi-asserted-by":"crossref","unstructured":"Jarvis B and Faulds D (1999) Etanercept: a review of its use in rheumatoid arthritis. Drugs 57: 945-966.","DOI":"10.2165\/00003495-199957060-00014"},{"key":"10.1124\/jpet.105.097568_bib16","doi-asserted-by":"crossref","unstructured":"Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HD, and Gaestel M (1999) MAPKAP kinase 2 is essential for LPS-induced TNF-a biosynthesis. Nat Cell Biol 1: 94-97.","DOI":"10.1038\/10061"},{"key":"10.1124\/jpet.105.097568_bib17","doi-asserted-by":"crossref","unstructured":"Kumar S, Boehm J, and Lee JC (2003) p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2: 717-726.","DOI":"10.1038\/nrd1177"},{"key":"10.1124\/jpet.105.097568_bib18","doi-asserted-by":"crossref","unstructured":"Kumar S, McDonnell PC, Gum RJ, Hand AT, Lee JC, and Young PR (1997) Novel homologs of CSBP\/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun 235: 533-538.","DOI":"10.1006\/bbrc.1997.6849"},{"key":"10.1124\/jpet.105.097568_bib19","doi-asserted-by":"crossref","unstructured":"Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, and Landvatter SW (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (Lond) 372: 739-746.","DOI":"10.1038\/372739a0"},{"key":"10.1124\/jpet.105.097568_bib20","doi-asserted-by":"crossref","unstructured":"Leftheris K, Ahmed G, Chan R, Dyckman AJ, Hussain Z, Ho K, Hynes J Jr, Letourneau J, Li W, Lin S, et al. (2004) The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase. J Med Chem 47: 6283-6291.","DOI":"10.1021\/jm049521d"},{"key":"10.1124\/jpet.105.097568_bib21","doi-asserted-by":"crossref","unstructured":"McLay IM, Halley F, Souness JE, McKenna J, Benning V, Birrell M, Burton B, Belvisi M, Collis A, Constan A, et al. (2001) The discovery of RPR200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy. Bioorg Med Chem 9: 537-554.","DOI":"10.1016\/S0968-0896(00)00331-X"},{"key":"10.1124\/jpet.105.097568_bib22","doi-asserted-by":"crossref","unstructured":"Natarajan SR, Wisnoski DD, Singh SB, Stelmach JE, O\u2019Neill EA, Schwartz CD, Thompson CM, Fitzgerald CE, O\u2019Keefe SJ, Kumar S, et al. (2003) p38 MAP kinase inhibitors. Part 1: design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold. Bioorg Med Chem Lett 13: 273-276.","DOI":"10.1002\/chin.200319152"},{"key":"10.1124\/jpet.105.097568_bib23","doi-asserted-by":"crossref","unstructured":"Onrust SV and Lamb HM (1998) Infliximab: a review of its use in Crohn\u2019s disease and rheumatoid arthritis. BioDrugs 10: 397-422.","DOI":"10.2165\/00063030-199810050-00006"},{"key":"10.1124\/jpet.105.097568_bib24","doi-asserted-by":"crossref","unstructured":"Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, Grob PM, Hickey ER, Moss N, Pav S, et al. (2002) Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 9: 268-272.","DOI":"10.1038\/nsb770"},{"key":"10.1124\/jpet.105.097568_bib25","doi-asserted-by":"crossref","unstructured":"Pearson G, Robinson F, Gibson TB, Xu BE, Karandikar M, Berman K, and Cobb MH (2001) Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22: 153-183.","DOI":"10.1210\/edrv.22.2.0428"},{"key":"10.1124\/jpet.105.097568_bib26","doi-asserted-by":"crossref","unstructured":"Raingeaud J, Whitmarsh AJ, Barrett T, Derijard B, and Davis RJ (1996) MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biol 16: 1247-1255.","DOI":"10.1128\/MCB.16.3.1247"},{"key":"10.1124\/jpet.105.097568_bib27","doi-asserted-by":"crossref","unstructured":"Salituro FG, Germann UA, Wilson KP, Bemis GW, Fox T, and Su MS-S (1999) Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Curr Med Chem 6: 807-823.","DOI":"10.2174\/092986730609220401150415"},{"key":"10.1124\/jpet.105.097568_bib28","doi-asserted-by":"crossref","unstructured":"Wadsworth SA, Cavender DE, Beers SA, Lalan P, Schafer PH, Malloy EA, Wu W, Fahmy B, Olini GC, Davis JE, et al. (1999) RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther 29: 680-687.","DOI":"10.1016\/S0022-3565(24)35155-9"},{"key":"10.1124\/jpet.105.097568_bib29","doi-asserted-by":"crossref","unstructured":"Wang XS, Diener K, Manthey CL, Wang SW, Rosenzweig B, Bray J, Delaney J, Cole CN, Chan-Hui PY, Mantlo N, et al. (1997) Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase. J Biol Chem 272: 23668-23674.","DOI":"10.1074\/jbc.272.38.23668"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524328113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524328113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.105.097568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T21:56:48Z","timestamp":1740002208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524328113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0022356524328113"],"URL":"https:\/\/doi.org\/10.1124\/jpet.105.097568","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery and Characterization of Triaminotriazine Aniline Amides as Highly Selective p38 Kinase Inhibitors","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.105.097568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2006 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}